ProfileGDS5678 / 1420297_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 41% 40% 40% 36% 39% 40% 42% 39% 39% 40% 40% 40% 40% 40% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9790341
GSM967853U87-EV human glioblastoma xenograft - Control 22.9230540
GSM967854U87-EV human glioblastoma xenograft - Control 32.9263940
GSM967855U87-EV human glioblastoma xenograft - Control 42.7736336
GSM967856U87-EV human glioblastoma xenograft - Control 52.8557739
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0167140
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.0461742
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8932139
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8737339
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.9031140
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9110340
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8765240
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9205640
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9146740